Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 392, Issue 11, pp 1401–1410 | Cite as

Role of protease-activated receptor 2 in regulation of renin synthesis and secretion in mice

  • Lena R. Thurner
  • Klaus HöcherlEmail author
Original Article


It has been reported that the serine protease kallikrein stimulates and that aprotinin, a protease inhibitor, inhibits renal renin secretion. Since direct stimulation of the protease-activated receptor (PAR) 2 increases renin secretion in isolated perfused mouse kidneys, we hypothesized that activation of PAR2 receptors by serine proteases could be involved in the synthesis and secretion of renin in vivo. We therefore determined the response of plasma renin concentration (PRC) to acute intraperitoneal administration of the PAR2 agonist SLIGRL, isoproterenol, hydralazine, furosemide, losartan, or lipopolysaccharide in conscious wild-type (WT) and Par2-deficient mice. Basal PRC was not different in Par2-deficient mice compared with WT mice. All six acute treatments caused significant increases of PRC in both WT and Par2-deficient mice. The response was significantly lower only in endotoxin-treated Par2-deficient mice. Chronic treatment with losartan, low salt intake, the combination of both, or furosemide caused an increase of PRC and renin mRNA in WT mice, whereas a high salt intake caused a decrease. Alterations in PRC and renal renin mRNA expression were not different between WT and Par2 -/- mice in response to chronic treatments. Par2-deficiency did not alter furosemide-induced diuresis and natriuresis. Systolic blood pressure responses to chronic treatments were not different between WT and Par2 -/- mice. In conclusion, deficiency of Par2 receptors does not alter renin secretion and renin gene expression modulated by a variety of typical maneuvers. However, activation of Par2 receptors by serine proteases seems to be of importance for renin secretion in the context of inflammation.


Renin Kidney F2RL1 Lipopolysaccharide Angiotensin 



The technical assistance provided by Ramona Mogge and Andrea Agli is gratefully acknowledged.

Author contribution statement

LRT and KH conceived and designed the research. LRT conducted the experiments. LRT and KH analyzed the data. KH wrote the manuscript. All authors read and approved the manuscript.

Compliance with ethical standards

All procedures were performed in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and were approved by the local animal protection committee.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. Abdallah RT, Keum JS, El-Shewy HM, Lee MH, Wang B, Gooz M, Luttrell DK, Luttrell LM, Jaffa AA (2010) Plasma kallikrein promotes epidermal growth factor receptor transactivation and signaling in vascular smooth muscle through direct activation of protease-activated receptors. J Biol Chem 285:35206–35215. CrossRefPubMedPubMedCentralGoogle Scholar
  2. Abe Y, Miura K, Imanishi M, Yukimura T, Komori T, Okahara T, Yamamoto K (1980) Effects of an orally active converting enzyme inhibitor (YS-980) on renal function in dogs. J Pharmacol Exp Ther 214:166–170PubMedGoogle Scholar
  3. Ayano Y, Yamasaki K, Soejima H, Ikegami K (1984) Interrelationships between the renal kallikrein-kinin and prostaglandin systems in furosemide-induced diuresis. Urol Int 39:52–57. CrossRefPubMedGoogle Scholar
  4. Beierwaltes WH, Prada J, Carretero OA (1985) Effect of glandular kallikrein on renin release in isolated rat glomeruli. Hypertension 7:27–31CrossRefGoogle Scholar
  5. Bertog M, Letz B, Kong W, Steinhoff M, Higgins MA, Bielfeld-Ackermann A, Fromter E, Bunnett NW, Korbmacher C (1999) Basolateral proteinase-activated receptor (PAR-2) induces chloride secretion in M-1 mouse renal cortical collecting duct cells. J Physiol 521(Pt 1):3–17CrossRefGoogle Scholar
  6. Castrop H, Schiessl IM (2014) Physiology and pathophysiology of the renal Na-K-2Cl cotransporter (NKCC2). Am J Physiol Renal Physiol 307:F991–F1002. CrossRefPubMedGoogle Scholar
  7. Castrop H, Schweda F, Mizel D, Huang Y, Briggs J, Kurtz A, Schnermann J (2004) Permissive role of nitric oxide in macula densa control of renin secretion. Am J Physiol Renal Physiol 286:F848–F857. CrossRefPubMedGoogle Scholar
  8. Castrop H, Hocherl K, Kurtz A, Schweda F, Todorov V, Wagner C (2010) Physiology of kidney renin. Physiol Rev 90:607–673. CrossRefPubMedGoogle Scholar
  9. Chou YH, Chu TS, Lin SL (2018) Role of renin-angiotensin system in acute kidney injury-chronic kidney disease transition. Nephrology (Carlton) 23(Suppl 4):121–125. CrossRefGoogle Scholar
  10. Chung H, Ramachandran R, Hollenberg MD, Muruve DA (2013) Proteinase-activated receptor-2 transactivation of epidermal growth factor receptor and transforming growth factor-beta receptor signaling pathways contributes to renal fibrosis. J Biol Chem 288:37319–37331. CrossRefPubMedPubMedCentralGoogle Scholar
  11. Cumming AD, Nimmo GR (1992) Hemodynamic, renal, and hormonal actions of aprotinin in an ovine model of septic shock. Crit Care Med 20:1134–1139CrossRefGoogle Scholar
  12. D’Andrea MR, Derian CK, Leturcq D, Baker SM, Brunmark A, Ling P, Darrow AL, Santulli RJ, Brass LF, Andrade-Gordon P (1998) Characterization of protease-activated receptor-2 immunoreactivity in normal human tissues. J Histochem Cytochem 46:157–164. CrossRefPubMedGoogle Scholar
  13. Damiano BP, Cheung WM, Santulli RJ, Fung-Leung WP, Ngo K, Ye RD, Darrow AL, Derian CK, de Garavilla L, Andrade-Gordon P (1999) Cardiovascular responses mediated by protease-activated receptor-2 (PAR-2) and thrombin receptor (PAR-1) are distinguished in mice deficient in PAR-2 or PAR-1. J Pharmacol Exp Ther 288:671–678PubMedGoogle Scholar
  14. Du C, Zhang T, Xiao X, Shi Y, Duan H, Ren Y (2017) Protease-activated receptor-2 promotes kidney tubular epithelial inflammation by inhibiting autophagy via the PI3K/Akt/mTOR signalling pathway. Biochem J 474:2733–2747. CrossRefPubMedGoogle Scholar
  15. Dudoignon E, Depret F, Legrand M (2019) Is the renin-angiotensin-aldosterone system good for the kidney in acute settings? Nephron:1–5.
  16. Facemire CS, Nguyen M, Jania L, Beierwaltes WH, Kim HS, Koller BH, Coffman TM (2011) A major role for the EP4 receptor in regulation of renin. Am J Physiol Renal Physiol 301:F1035–F1041. CrossRefPubMedPubMedCentralGoogle Scholar
  17. Gardiner SM, Kemp PA, March JE, Bennett T (1996) Temporal differences between the involvement of angiotensin II and endothelin in the cardiovascular responses to endotoxaemia in conscious rats. Br J Pharmacol 119:1619–1627CrossRefGoogle Scholar
  18. Gui Y, Loutzenhiser R, Hollenberg MD (2003) Bidirectional regulation of renal hemodynamics by activation of PAR1 and PAR2 in isolated perfused rat kidney. Am J Physiol Renal Physiol 285:F95–F104. CrossRefGoogle Scholar
  19. Harris RC, Martinez-Maldonado M (1995) Angiotensin II-mediated renal injury. Miner Electrolyte Metab 21:328–335PubMedGoogle Scholar
  20. Hocherl K, Dreher F, Vitzthum H, Kohler J, Kurtz A (2002) Cyclosporine a suppresses cyclooxygenase-2 expression in the rat kidney. J Am Soc Nephrol 13:2427–2436CrossRefGoogle Scholar
  21. Hocherl K, Schmidt C, Kurt B, Bucher M (2010) Inhibition of NF-kappaB ameliorates sepsis-induced downregulation of aquaporin-2/V2 receptor expression and acute renal failure in vivo. Am J Physiol Renal Physiol 298:F196–F204. CrossRefPubMedGoogle Scholar
  22. Hocherl K, Gerl M, Schweda F (2011) Proteinase-activated receptors 1 and 2 exert opposite effects on renal renin release. Hypertension 58:611–618. CrossRefPubMedGoogle Scholar
  23. Hwa JJ, Ghibaudi L, Williams P, Chintala M, Zhang R, Chatterjee M, Sybertz E (1996) Evidence for the presence of a proteinase-activated receptor distinct from the thrombin receptor in vascular endothelial cells. Circ Res 78:581–588CrossRefGoogle Scholar
  24. Jesmin S, Gando S, Zaedi S, Prodhan SH, Sawamura A, Miyauchi T, Hiroe M, Yamaguchi N (2009) Protease-activated receptor 2 blocking peptide counteracts endotoxin-induced inflammation and coagulation and ameliorates renal fibrin deposition in a rat model of acute renal failure. Shock 32:626–632. CrossRefPubMedGoogle Scholar
  25. Kawao N, Ikeda H, Kitano T, Kuroda R, Sekiguchi F, Kataoka K, Kamanaka Y, Kawabata A (2004) Modulation of capsaicin-evoked visceral pain and referred hyperalgesia by protease-activated receptors 1 and 2. J Pharmacol Sci 94:277–285CrossRefGoogle Scholar
  26. Kim SM, Chen L, Faulhaber-Walter R, Oppermann M, Huang Y, Mizel D, Briggs JP, Schnermann J (2007a) Regulation of renin secretion and expression in mice deficient in beta1- and beta2-adrenergic receptors. Hypertension 50:103–109. CrossRefPubMedGoogle Scholar
  27. Kim SM, Chen L, Mizel D, Huang YG, Briggs JP, Schnermann J (2007b) Low plasma renin and reduced renin secretory responses to acute stimuli in conscious COX-2-deficient mice. Am J Physiol Renal Physiol 292:F415–F422. CrossRefPubMedGoogle Scholar
  28. Kobayashi M, Suzuki S, Hashiba K (1983) Role of renal kallikrein in control of renin release in conscious rats. Am J Phys 244:E262–E265. CrossRefGoogle Scholar
  29. MacGilchrist A, Craig KJ, Hayes PC, Cumming AD (1994) Effect of the serine protease inhibitor, aprotinin, on systemic haemodynamics and renal function in patients with hepatic cirrhosis and ascites. Clin Sci 87:329–335CrossRefGoogle Scholar
  30. Madeddu P, Oppes M, Soro A, Dessi’-Fulgheri P, Glorioso N, Bandiera F, Manunta P, Rubattu S, Rappelli A (1987) The effects of aprotinin, a kallikrein inhibitor, on renin release and urinary sodium excretion in mild essential hypertensives. J Hypertens 5:581–586CrossRefGoogle Scholar
  31. Margolius HS, Chao J, Kaizu T (1976) The effects of aldosterone and spironolactone on renal kallikrein in the rat. Clin Sci Mol Med Suppl 3:279s–282sPubMedGoogle Scholar
  32. Matzdorf C, Kurtz A, Hocherl K (2007) COX-2 activity determines the level of renin expression but is dispensable for acute upregulation of renin expression in rat kidneys. Am J Physiol Renal Physiol 292:F1782–F1790. CrossRefPubMedGoogle Scholar
  33. Mederle K, Schweda F, Kattler V, Doblinger E, Miyata K, Hocherl K, Oike Y, Castrop H (2013) The angiotensin II AT1 receptor-associated protein Arap1 is involved in sepsis-induced hypotension. Crit Care 17:R130. CrossRefPubMedPubMedCentralGoogle Scholar
  34. Mederle K, Meurer M, Castrop H, Hocherl K (2015) Inhibition of COX-1 attenuates the formation of thromboxane A2 and ameliorates the acute decrease in glomerular filtration rate in endotoxemic mice. Am J Physiol Renal Physiol 309:F332–F340. CrossRefPubMedGoogle Scholar
  35. Meurer M, Ebert K, Schweda F, Hocherl K (2018) The renal vasodilatory effect of prostaglandins is ameliorated in isolated-perfused kidneys of endotoxemic mice. Pflugers Archiv: Eur J Physiol 470:1691–1703. CrossRefGoogle Scholar
  36. Morla L, Brideau G, Fila M, Crambert G, Cheval L, Houillier P, Ramakrishnan S, Imbert-Teboul M, Doucet A (2013) Renal proteinase-activated receptor 2, a new actor in the control of blood pressure and plasma potassium level. J Biol Chem 288:10124–10131. CrossRefPubMedPubMedCentralGoogle Scholar
  37. Muller MW, Todorov V, Kramer BK, Kurtz A (2002) Angiotensin II inhibits renin gene transcription via the protein kinase C pathway. Pflugers Archiv: Eur J Physiol 444:499–505. CrossRefGoogle Scholar
  38. Nasjletti A, Malik KU (1981) The renal kallikrein-kinin and prostaglandin systems interaction. Annu Rev Physiol 43:597–609. CrossRefPubMedGoogle Scholar
  39. Neubauer B, Schrankl J, Steppan D, Neubauer K, Sequeira-Lopez ML, Pan L, Gomez RA, Coffman TM, Gross KW, Kurtz A, Wagner C (2018) Angiotensin II short-loop feedback: is there a role of Ang II for the regulation of the renin system in vivo? Hypertension 71:1075–1082. CrossRefPubMedPubMedCentralGoogle Scholar
  40. Okamura T, Inagami T (1984) Release of active and inactive renin from hog renal cortical slices in vitro. Am J Phys 246:F765–F771. CrossRefGoogle Scholar
  41. Overlack A, Stumpe KO, Kuhnert M, Heck I (1980) Altered blood pressure and renin responses to converting enzyme inhibition after aprotinin-induced kallikrein-kinin-system blockade. Clin Sci 59(Suppl 6):129s–132sCrossRefGoogle Scholar
  42. Overlack A, Stumpe KO, Muller HM, Kolloch R, Higuchi M (1982) Interactions of diuretics with the renal kallikrein-kinin and prostaglandin systems. Klin Wochenschr 60:1223–1228CrossRefGoogle Scholar
  43. Pinet F, Mizrahi J, Laboulandine I, Menard J, Corvol P (1987) Regulation of prorenin secretion in cultured human transfected juxtaglomerular cells. J Clin Invest 80:724–731. CrossRefPubMedPubMedCentralGoogle Scholar
  44. Rhaleb NE, Yang XP, Carretero OA (2011) The kallikrein-kinin system as a regulator of cardiovascular and renal function. Compr Physiol 1:971–993. CrossRefPubMedPubMedCentralGoogle Scholar
  45. Schweda F, Wagner C, Kramer BK, Schnermann J, Kurtz A (2003) Preserved macula densa-dependent renin secretion in A1 adenosine receptor knockout mice. Am J Physiol Renal Physiol 284:F770–F777. CrossRefPubMedGoogle Scholar
  46. Sealey JE, Overlack A, Laragh JH, Stumpe KO, Atlas SA (1981) Effect of captopril and aprotinin on inactive renin. J Clin Endocrinol Metab 53:626–630. CrossRefPubMedGoogle Scholar
  47. Seto S, Kher V, Scicli AG, Beierwaltes WH, Carretero OA (1983) The effect of aprotinin (a serine protease inhibitor) on renal function and renin release. Hypertension 5:893–899CrossRefGoogle Scholar
  48. Shah R (2009) Protease-activated receptors in cardiovascular health and diseases. Am Heart J 157:253–262. CrossRefPubMedGoogle Scholar
  49. Shimoda K, Lee TC, Maxwell MH (1983) Inhibition of furosemide-induced increases in plasma renin activity by amiloride. Hypertension 5:706–711CrossRefGoogle Scholar
  50. Soh UJ, Dores MR, Chen B, Trejo J (2010) Signal transduction by protease-activated receptors. Br J Pharmacol 160:191–203. CrossRefPubMedPubMedCentralGoogle Scholar
  51. Song Q, Wang DZ, Harley RA, Chao L, Chao J (1996) Cellular localization of low-molecular-weight kininogen and bradykinin B2 receptor mRNAs in human kidney. Am J Phys 270:F919–F926. CrossRefGoogle Scholar
  52. Sparks MA, Crowley SD, Gurley SB, Mirotsou M, Coffman TM (2014) Classical renin-angiotensin system in kidney physiology. Compr Physiol 4:1201–1228. CrossRefPubMedPubMedCentralGoogle Scholar
  53. Suzuki S, Franco-Saenz R, Tan SY, Mulrow PJ (1980) Direct action of rat urinary kallikrein on rat kidney to release renin. J Clin Invest 66:757–762. CrossRefPubMedPubMedCentralGoogle Scholar
  54. Suzuki S, Franco-Saenz R, Tan SY, Mulrow PJ (1981) Direct action of kallikrein and other proteases on the renin-angiotensin system. Hypertension 3:I13–I17PubMedGoogle Scholar
  55. Suzuki S, Kobayashi M, Hashiba K (1986) The role of renal kallikrein and prostaglandin in the control of renin release. Jpn Heart J 27:83–93CrossRefGoogle Scholar
  56. Todorov V, Muller M, Schweda F, Kurtz A (2002) Tumor necrosis factor-alpha inhibits renin gene expression. Am J Physiol Regul Integr Comp Physiol 283:R1046–R1051. CrossRefPubMedGoogle Scholar
  57. Wagner C, de Wit C, Gerl M, Kurtz A, Hocherl K (2007) Increased expression of cyclooxygenase 2 contributes to aberrant renin production in connexin 40-deficient kidneys. Am J Physiol Regul Integr Comp Physiol 293:R1781–R1786. CrossRefPubMedGoogle Scholar
  58. Watanabe M, Oe Y, Sato E, Sekimoto A, Sato H, Ito S, Takahashi N (2019) Protease-activated receptor 2 exacerbates cisplatin-induced nephrotoxicity. Am J Physiol Renal Physiol 316:F654–F659. CrossRefPubMedGoogle Scholar
  59. Xu Y, Zacharias U, Peraldi MN, He CJ, Lu C, Sraer JD, Brass LF, Rondeau E (1995) Constitutive expression and modulation of the functional thrombin receptor in the human kidney. Am J Pathol 146:101–110PubMedPubMedCentralGoogle Scholar
  60. Yang T, Xu C (2017) Physiology and pathophysiology of the intrarenal renin-angiotensin system: an update. J Am Soc Nephrol 28:1040–1049. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Institute of Experimental and Clinical Pharmacology and ToxicologyFriedrich-Alexander-Universität Erlangen-Nürnberg (FAU)ErlangenGermany

Personalised recommendations